For this purpose, the CHLA-20 neuroblastoma spheroid viability assay (168 h) was used in the presence and absence of 100 and 1000 nM sGD2, and the area under the viability curve (%*h) was calculated and plotted (Figure 8). The gene discussed is SMARCD2; the disease is neuroblastoma.